Articles related to BREAST CANCER

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.

The Trop-2-directed antibody-drug conjugate demonstrated a 2.3-month improvement in progression-free survival compared to standard chemotherapy options, offering a new treatment pathway for patients with limited options.

One in eight women will develop breast cancer in her lifetime, with risk-reducing medications showing up to 65% reduction in annual incidence, yet these interventions remain vastly underutilized in clinical practice.

The case highlights the critical importance of thorough documentation and appropriate follow-up care, regardless of a patient’s age or statistical likelihood of serious conditions.

Breast cancer surgical management requires ongoing patient education to address persistent misconceptions about treatment options and outcomes.

The inavolisib-based regimen more than doubled progression-free survival in PIK3CA-mutated breast cancers, offering a new standard of care for this challenging patient population.